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Abstract
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine
kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal
hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic
collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral
circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under
sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the
azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the
first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic
patients.
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Introduction
Cirrhosis is a major public health problem, most commonly
caused by alcoholism or viral hepatitis. Complications from
advanced cirrhosis include hepatocellular carcinoma (HCC) and
portal hypertension. Portal hypertension is characterized by a
increased blood flow in the splanchnic organs draining into the
portal vein and by the formation of porto-systemic collateral
vessels, including gastroesophageal varices that can rupture and
cause life-threatening bleeding[1,2] Current pharmacotherapy for
portal hypertension is limited to beta-blockers, but these drugs
have an unpredictable response and can cause significant adverse
events. [1,3,4]
One of the underlying causes of cirrhotic portal hypertension is
the growth of collateral circulation [2]. In recent years, it has
become increasingly evident that disturbances in the liver
microcirculation, hypoxia and angiogenesis may occur in the
injured liver and that angiogenesis plays a key role in the
progression of liver fibrosis [5]. In experimental models of portal
hypertension, a number of receptor tyrosine kinase inhibitors,
including imatinib, sunitinib and sorafenib, have been shown to
regulate splanchnic neovascularization and improve portal
hypertension [6,7]. Hence, receptor tyrosine kinase inhibitors
offer a promising new approach to the management of portal
hypertension.[8,9]
Sorafenib (BAY-43-9006 NexavarH, Bayer Pharmaceuticals
Corp., Wayne NJ and Onyx Pharmaceuticals Inc., Emeryville
CA), an oral multikinase inhibitor of the VEGF and the PDGF
receptors and Raf, decreases tumor growth and inhibits
angiogenesis in advanced HCC [10,11,12]. Sorafenib is already
in clinical use as an anticancer drug that targets tumour cell
proliferation and angiogenesis [11] and is approved for
treatment of renal cell carcinoma [13] and for HCC [10]. Also,
sorafenib has demonstrated clinical activity in various malig-
nancies, including lung cancer,[ 1 4 ]t h y r o i dc a n c e r ,[ 1 5 ]a n d
soft tissue sarcomas [16,17]. In advanced HCC (Child–Pugh
class A), sorafenib is the only nonsurgical and nonradiological
treatment to have demonstrated efficacy in improving survival
in this disease.
However, sorafenib can lead to endothelial injury and promote
vascular leakage, and is not approved for patients with portal
hypertension complicated by cirrhosis of the liver and advanced
HCC (Child–Pugh class B to C), even in the absence of
gastrointestinal bleeding. [10,11,12]
It has been recently demonstrated in preclinical studies that
sorafenib had a beneficial effect on porto-collateral circulation in
cirrhotic animal with portal hypertension. [8,18] However, no
data have been presented at this time in humans. We report here
portocollateral circulation changes in cirrhotic patients with
advanced HCC treated with sorafenib.
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Patient Population
Seven patients with advanced-stage HCC and portal hyperten-
sion were treated with sorafenib, at a validated dose of 400 mg
twice daily until there was evidence of disease progression.
Sorafenib was administered at 50% of the planned dose if any
severe adverse events related to the study drug occurred, and in
frail patients.[10] In sorafenib group, treatment interruptions and
up to two dose reductions (first to 400 mg once daily and then to
400 mg every 2 days) were done in case of drug-related adverse
effects. If further dose reductions were required, patients were
withdrawn from the study. Treatment continued until the
occurrence of either radiologic progression, as defined by RECIST
criteria [19] or symptomatic progression.
Patients were included in the study if they fulfilled inclusion
criteria and agreed to undergo repeat Magnetic Resonance
Imaging during follow-up. None of the patients included in the
present study received beta-blockers, in order to avoid confusion in
the respective roles of beta-blockers and sorafenib on portal
venous flow. Seven patients received at least one month of
sorafenib therapy and underwent a second Magnetic Resonance
Imaging. In a control group, the first nine patients who fulfilled the
inclusion criteria and accepted repeated Magnetic Resonance
Imaging were included.
An evaluation of porto-collateral circulations using a magnetic
resonance technique was done before starting treatment, and at
day 30. Five out of seven had a post therapy evaluation 30 days
after withdrawal of sorafenib. To evaluate porto-collateral
modification in cirrhotic patients, nine cirrhotic patients (control
group) received an evaluation of porto-collateral circulations using
a magnetic resonance technique was done at day 0 and day 30. All
patients presented a normal blood pressure and no patients
received beta-blocker therapy.
Assessment of Blood Flow
Flow in the azygos vein and the portal venous systems were
quantified with cine-phase contrast magnetic resonance imaging
velocity mapping. [20,21] Magnetic resonance imaging examina-
tions were performed with a 1.5 T MR unit (Siemens Medical
Solutions, Avanto, Erlangen, Germany) with electrocardiographic
gating, using a cardiac dedicated 32-channel phased-array coil,
and parallel acquisition to reduce the duration of acquisition. The
time resolution was 16 frames in one cardiac cycle. Azygos flow
was measured at the mid-thoracic level. Anatomical evaluation of
the azygos and portal venous systems with axial, coronal, and
oblique breath-hold sequences was performed to ensure the
correct acquisition plane, perpendicular to the vein for flow
quantification. Each set was reconstructed to yield a magnitude
image and a velocity encoded phase-contrast image. Portal flow
was measured in the main segment 20 mm proximal to the portal
bifurcation. Volumetric flow rate was obtained from the product
of the cross-sectional area and the velocity. Hand-drawn circular
regions of interest were placed on the magnitude images so that all
pixels of the vessel were included (Fig. 1).
Magnetic Resonance Imaging using phase-contrast velocity
allows for direct non-invasive quantification evaluation of flow
dynamics. Magnetic resonance Imaging was used to prevent flow
variability measurements and to allow azygos venous flow
evaluation. Phase-contrast Magnetic Resonance Imaging flow
has the advantage to avoid intravenous injection of contrast media
in this frail population. Phase-contrast flows measurements have
been validated in vitro [22] as well as in vivo, including as an
evaluation technique of the portal [23] and azygos venous flows
[24]. Also, Magnetic Resonance Imaging Phase-contrast is a
reproducible technique compared to ultrasonographic examina-
tion, which is a simpler technique but suffered from a high
variability in repeated measurements. The Magnetic Resonance
Imaging technique could help to improve Doppler flow calcula-
tions, thereby allowing standardization of protocols.
Results
Patient Characteristics
Between October 2009 and July 2010, 7 patients with
advanced-stage HCC received sorafenib therapy according to
the schedule described above and 9 patients were included in the
control group. The patients’ characteristics are shown in Table 1.
Both in sorafenib group and in control group, the disease at
baseline was rate as Child-Pugh class A or B. Chronic hepatitis C
virus and alcohol were the predominant causes of liver disease in
both group. There were no relevant differences between the two
groups with respect to previous anti tumor therapy for HCC. Two
(29%) patients had undergone surgery for HCC, and six (86%)
had received prior transarterial chemoembolization therapy.
Toxicity
All patients from sorafenib group reported cutaneous adverse
events and one patient developed a grade 3 hand-foot reaction
necessitating discontinuation of sorafenib. There were no reports
of hypertension or renal toxicity. In both groups, no patients had
deterioration of liver function, history of esophageal variceal
bleeding or an introduction of a beta-blocker therapy during the
period of monitoring. None of the patients were rehospitalized for
reasons related to acute toxicity of sorafenib. Either in sorafenib
group or in control group, no patient experienced specific cirrhosis
complications such as acute oesophageal variceal bleeding or renal
dysfunction during the study.
Blood Flow
At baseline, all patients had portal venous blood flow, values
consistent with those observed in control group or previously
described in cirrhotic patients (Table 2). [25] Patients from control
group had no modification of porto-collateral circulations during
the period of monitoring while patients under sorafenib therapy
had a decrease in portal venous flow of at least 36% (Fig. 2a). At
withdrawal, portal venous flow seeks to recover values before
sorafenib. In contrast, no specific change was observed in the
azygos vein or the abdominal aorta (Fig. 2b, c).
Anti-Tumor Activity
At the time of analysis, two patients were still alive. At first
assessment, patients achieved either a partial response or stable
disease. Median progression free survival and overall survival were
153 days and 301 days respectively.
Discussion
We report a significant reduction in portal venous flow (54% of
mean portal venous flow) in seven patients with advanced HCC
receiving sorafenib. Sorafenib is a potent multikinase inhibitor that
targets the Raf/MEK/ERK pathway, as well as VEGFR1/2/3,
PDGFR-b, KIT, Flt-3, and RET,[11] and has been approved in
several countries worldwide for the treatment of renal cell
carcinoma and HCC.[10,13] In the SHARP study, sorafenib
was both effective and safe in patients with advanced
HCC,[10,11,12] but Child–Pugh liver function class B or C was
an exclusion criterion.[10] Importantly, this classification does not
Portal Venous Flow and Sorafenib
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of biological and clinical complications of cirrhosis. [26]
Receptor tyrosine kinase inhibitors have begun to receive a
greater attention as a potential therapy in the treatment of portal
hypertension and cirrhosis. [9] In our series, we highlight for the
first time the positive side effect of sorafenib on portal
hypertension. Our study confirms in the clinical setting the
findings of previous preclinical studies. However, the generaliza-
tion of our results is made difficult by the small population size.
Therefore, a larger study is warranted to confirm our results. Our
data suggest a beneficial effect in a one-month survey, but data are
lacking on sorafenib long-term effects on portal venous flow. Also,
one patient out of seven received a lower dose of sorafenib,
showing a maintained effect on portal venous flow even at low
doses. This case raises the question about the optimal dose to
control portal venous flow, which could be explored in a phase I
study.
In sorafenib group, 3 patients (43%) received 50% of the
planned dose, resulting in a mean decrease of the portal venous
flow of 32%. Those data suggest that a smaller dose of sorafenib
than the one validated for HCC is able to decrease portal venous
flow and modulate porto-collateral circulation.
Portal hypertension is the most important complication and the
leading cause of mortality worldwide in patients with chronic liver
diseases. [27] A characteristic feature of portal hypertension is the
development of hyperdynamic splanchnic organs draining into the
portal vein and subsequent portal venous inflow. Fernandez et al.
[28,29,30] demonstrated that an increase in the splanchnic
vascular bed size mediated by a VEGF-dependent angiogenic
process contributed significantly to increased overall blood flow in
splanchnic tissues in animal models of portal hyperten-
sion.[28,29,30] Interestingly, Mejias et al. showed that the effect
of sorafenib daily were observed not only in the intrahepatic
circulation, but also in the systemic and collaterals circulations
suggesting the benefit of sorafenib in portal hypertension [8]. In
our study, all patients receiving sorafenib therapy decrease portal
venous flow and mean portal venous flow recovers its initial after
sorafenib withdrawal. Those data are not related with a
degradation of cirrhosis because no deterioration of the liver
function was observed within the period.
Anti-VEGF agents are associated with an increased risk of
bleeding. Most bleeding events are mild (grade 1–2), and may
occur at any site (not specifically in the gastro-intestinal tract) [31].
On the other hand, cirrhotic patients do present a higher risk of
bleeding events than the general population. As an illustration, in
Abou-alfa study focusing on this frail population, only one out of
137 patients receiving sorafenib develops a grade 5 intracranial
haemorrhage [32]. Also, patients receiving sunitinib do present a
higher risk of bleeding events than those receiving sorafenib [31].
Je et al, in a systematic review and a meta-analysis of clinical trials
showed for all grade bleeding a relative risk of 1.86 (1.33–2.6,
p,0.0001) and for high grade bleeding a relative risk of 1.16
Figure 1. Female Patient, Aged 56 Years (Patient 2). Coronal (a) and transaxial (b) localizing image planned along the course of the portal vein
(line). Based on these images, a phase-contrast enconding sequence was planned perpendicular to the course of the portal vein (line). c: Portal vein
(arrowhead) velocity-encoded phase-contrast image. d: Portal vein (arrow) magnitude image.
doi:10.1371/journal.pone.0016978.g001
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observed in our study, possibly due to the small size of patients’
population.
VEGF-dependent angiogenesis plays a crucial role in the
formation of portal collateral vessels.[28,29,30] Interestingly,
Fernandez et al. suggested that the dual inhibition of VEGF-
and PDGF-signaling pathways significantly reduced splanchnic
neovascularization and pericyte coverage of neovessels, and
translated into hemodynamic effects as a 40% decrease in portal
pressure in a rat model.[33]
Meijas et al. demonstrated beneficial effects of sorafenib on
intra-hepatic and portal circulations in cirrhotic rats.[8] It has also
been shown to reduce portal pressure, superior mesenterial artery
blood flow, and porto-systemic collateral blood flow in non
cirrhotic rats with prehepatic portal hypertension, without
affecting systemic hemodynamics.[18] Similarly, our present data
suggest that sorafenib decreases portal venous blood flow without
modifying aortic blood flow or azygos venous blood flow in
patients with advanced HCC. Since HCC is a common
complication of advanced cirrhosis, sorafenib is currently being
used in patients with portal hypertension. Sorafenib should
therefore be considered as an option to decrease portal
hypertension in cirrhotic patients with advanced HCC.
Although beta blockers and endoscopic therapy are the only
therapies proven to prevent portal hypertension induced bleeding,
our data suggest that sorafenib might have a positive effect on
portal venous flow. Hence, further studies should evaluate the
impact of sorafenib compared to that of beta-blockers.
The dual inhibition of the VEGF- and PDGF-signaling
pathways induced by sorafenib likely accounts for the decrease
in portal venous flow observed in our patients. It has been
suggested that the VEGF-signaling pathway is required not only
for the development but also for the maintenance of portal
hypertension.[8,33] Consequently, inhibition of this pathway
results in a significant attenuation of portal pressure and in
reversal of the hyperdynamic splanchnic circulation in rats with
advanced portal hypertension.[33] Those findings are consistent
with our present data in humans, indicating up to an 84%
decrease in mean portal venous flow within 30 days on sorafenib
therapy, and a complete reversible effect in portal venous flow 30
days after sorafenib withdrawal.
Ebos et al. [34] have shown in preclinical models that priming
with anti-VEGF agents promote tumour growth and dissemina-
tion. These findings suggest that short-term anti-VEGF therapy
induces a ‘‘metastatic conditioning’’ in healthy organs. Hence, one
could expect that short-term treatment of cirrhotic patients with
sorafenib could promote tumour growth of a forthcoming cancer.
So far, portal hypertension therapies such as beta blockers are
introduced as soon as the portal hypertension is diagnosed, and
pursued continuously until death. As well, in line with the results of
Ebos et al. [34], we postulate that sorafenib might be administered
indefinitely, thereby avoiding the deleterious effects observed at
withdrawal of anti-VEGF therapy.
Sorafenib is the first drug to demonstrate a survival benefit and
manageable side effects in patients with advanced HCC Child–
Pugh class A. [10] Our data in patients with advanced HCC show
a consistent decrease in portal pressure within 30 days of therapy,
suggesting that sorafenib may also represent an option for patients
Table 1. Patients Characteristics.
Sorafenib Group Control Group
Patients 7 9
Age (years) 62.8 6 15.7 52.9 6 11.4
Sex (%) Male/Female 57/43 100/0






















- Hepatitis C only 3 3
- Hepatitis B only 2 0
- Alcohol only 1 3
-O t h e r 2 3
Oesophageal Varices
Grade 0/I/II 1/3/3 1/4/4
Advanced Hepatocellular Carcinoma 7 -
Prior therapy
- Surgical resection 2
- Locoregional therapy
- Transarterial Chemoembolization 6
- Radiofrequency ablation 1
- Systemic anticancer therapy 1
doi:10.1371/journal.pone.0016978.t001
Table 2. Venous Flow at base line.
Sorafenib
Group Control Group
Magnetic resonance imaging 7 9
Portal Vein
Portal Flow (ml/s) 6.262.9 7.263.9
Portal Velocity (cm/s) 8.563.9 9.163.6
Peak Portal Velocity (cm/s) 11.764.7 13.863.9
Azygos Vein
Azygos Flow (ml/s) 2.962.6 2.461.2
AzygosVelocity (cm/s) 13.664.7 10.463.4
Peak Azygos Velocity (cm/s) 25.866.3 20.467.0
Abdominal Aorta
Aortic Flow (ml/s) 36.1619 55.9620.6
Aortic Velocity (cm/s) 13.464.2 23.566.2
Peak Aortic Velocity (cm/s) 53.5619.8 70.6616.4
Results are expressed as mean 6 SD.
doi:10.1371/journal.pone.0016978.t002
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findings deserve further investigation in larger prospective trials.
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